Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

Abstract:

BACKGROUND:Consensus on what constitutes a quality colonoscopy report for patients with inflammatory bowel disease (IBD) is lacking. We developed a template for quality colonoscopy reporting that can be used broadly by endoscopists. METHODS:After a literature review of topics relevant to colonoscopy reporting, members of the Building Research in Inflammatory Bowel Disease Globally (BRIDGe) group and 2 external experts proposed candidate reporting elements. The RAND/University of California, Los Angeles appropriateness method was applied to rate the importance and feasibility of elements for inclusion in colonoscopy reports for patients with IBD. Panelists used the modified Delphi method to anonymously rate the importance and feasibility of candidate elements on a 1-to-9 scale (1-3: not important/feasible, 4-6: moderately important/feasible, 7-9: very important/feasible). Disagreement was assessed using a validated index. The panelists then met in person for discussion followed by a second round of voting. Elements rated a median of 7 or higher on importance after rerating were retained. RESULTS:One hundred two reporting elements were proposed. A total of 48 elements were retained across the four themes of "disease background," "findings and interventions," "Crohn's disease with an ileocolonic anastomosis," and "pouchoscopy." CONCLUSIONS:A comprehensive list of recommended elements for quality IBD colonoscopy reporting stratified by clinical scenario has been described, using a rigorous and evidence-based approach. These elements can be incorporated into endoscopy reporting software platforms. Standardized endoscopy reporting may improve the quality of care in IBD.

journal_name

Inflamm Bowel Dis

authors

Devlin SM,Melmed GY,Irving PM,Rubin DT,Kornbluth A,Kozuch PL,Raffals LE,Velayos FS,Sparrow MP,Baidoo L,Bressler B,Cheifetz AS,Jones J,Kaplan GG,Siegel CA

doi

10.1097/MIB.0000000000000764

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

1418-24

issue

6

eissn

1078-0998

issn

1536-4844

journal_volume

22

pub_type

共识发展会议,杂志文章
  • Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

    abstract::Three receptor tyrosine kinases, Tyro3, Axl, and Mertk (TAM) and their ligands Gas6 and Protein S, have emerged as potent negative regulators of innate immune responses. A number of studies using genetic ablation of TAM loci in mice have elucidated the mechanism of TAM engagement and function during the immune respons...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000050

    authors: Rothlin CV,Leighton JA,Ghosh S

    更新日期:2014-08-01 00:00:00

  • Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis.

    abstract:BACKGROUND/AIMS:The plant sterol guggulsterone has been shown to have anti-inflammatory properties. It remains unknown, however, whether guggulsterone is effective for the treatment of inflammatory bowel disease (IBD). Therefore, we investigated anti-inflammatory effects of guggulsterone on intestinal epithelial cells ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000235830.94057.c6

    authors: Cheon JH,Kim JS,Kim JM,Kim N,Jung HC,Song IS

    更新日期:2006-12-01 00:00:00

  • Short pediatric Crohn's disease activity index for quality improvement and observational research.

    abstract:BACKGROUND:Practical and objective instruments to assess pediatric Crohn's disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohn's Disease Activity Index (PCDAI) and the Abbreviated PCDAI (APCDAI); an...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21452

    authors: Kappelman MD,Crandall WV,Colletti RB,Goudie A,Leibowitz IH,Duffy L,Milov DE,Kim SC,Schoen BT,Patel AS,Grunow J,Larry E,Fairbrother G,Margolis P

    更新日期:2011-01-01 00:00:00

  • Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

    abstract:Background:We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods:Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy171

    authors: Shmidt E,Kochhar G,Hartke J,Chilukuri P,Meserve J,Chaudrey K,Koliani-Pace JL,Hirten R,Faleck D,Barocas M,Luo M,Lasch K,Boland BS,Singh S,Vande Casteele N,Sagi SV,Fischer M,Chang S,Bohm M,Lukin D,Sultan K,Swamina

    更新日期:2018-10-12 00:00:00

  • Flavaglines Ameliorate Experimental Colitis and Protect Against Intestinal Epithelial Cell Apoptosis and Mitochondrial Dysfunction.

    abstract:BACKGROUND:Flavaglines are a family of natural compounds shown to have anti-inflammatory and cytoprotective effects in neurons and cardiomyocytes. Flavaglines target prohibitins as ligands, which are scaffold proteins that regulate mitochondrial function, cell survival, and transcription. This study tested the therapeu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000592

    authors: Han J,Zhao Q,Basmadjian C,Désaubry L,Theiss AL

    更新日期:2016-01-01 00:00:00

  • Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.

    abstract:BACKGROUND:Female patients receiving immunosuppressive therapy may be at increased risk for human papillomavirus (HPV) infection and cervical neoplasia. METHODS:We administered the 3-dose HPV vaccine Gardasil to 37 females aged 9 to 26 years with inflammatory bowel disease (IBD) prescribed immunosuppressive therapy (p...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318281341b

    authors: Jacobson DL,Bousvaros A,Ashworth L,Carey R,Shrier LA,Burchett SK,Renna H,Lu Y

    更新日期:2013-06-01 00:00:00

  • Immune System Activation in C3H/HeJBir Mice Exhibiting Spontaneous Perianal Ulceration.

    abstract::: We report our initial characterization of the immune system in C3H/HeJBir mice that spontaneously develop perianal ulceration. Analysis of lymphokine production by mucosal and systemic lymphoid cells obtained from these mice revealed higher levels of interleukin (IL)4 in supernatants of in vitro stimulated Peyer's p...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Tonkonogy SL,Sartor BR

    更新日期:1997-04-01 00:00:00

  • Stopping Biologics in IBD-What Is the Evidence?

    abstract::Biologic treatments have revolutionized the way we treat inflammatory bowel disease patients (IBD). Anti-tumor necrosis factor (anti-TNF) antibodies are superior to conventional therapies to achieve sustained remission without steroids and mucosal healing. The objective of IBD treatment has evolved from symptom allevi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izx098

    authors: Louis E

    更新日期:2018-03-19 00:00:00

  • Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease.

    abstract::Tolerance, the regulated inability to respond to a specific immunologic stimulant, is a physiological event important to normal immune function. Just as loss of tolerance to self-proteins results in autoimmune diseases, we assert that loss of tolerance to commensal flora in the intestinal lumen leads to inflammatory b...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200407000-00023

    authors: Jump RL,Levine AD

    更新日期:2004-07-01 00:00:00

  • Reciprocal regulation of the survival and apoptosis of Th17 and Th1 cells in the colon.

    abstract:BACKGROUND:The immediate early response gene X-1 (IEX-1) is a stress-inducible gene involved in the regulation of cell growth, apoptosis and inflammation. METHODS:Acute colitis was induced by treatment of IEX-1 knockout (KO) and wild type (WT) control mice with dextran sulfate sodium (DSS), whereas chronic colitis was...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21772

    authors: Ustyugova IV,Zhi L,Wu MX

    更新日期:2012-02-01 00:00:00

  • Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.

    abstract:BACKGROUND:Ulcerative colitis (UC), a chronic, relapsing, and remitting inflammatory bowel disease, requires long-term treatment to maintain remission. In this study, the long-term safety and tolerability of mesalamine granules (MG) therapy was evaluated in the maintenance of UC remission. Previous prospective studies ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000076

    authors: Lichtenstein GR,Barrett AC,Bortey E,Paterson C,Forbes WP

    更新日期:2014-08-01 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

    abstract:BACKGROUND:Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We studied the pharmacokinetics, pharmacodynamics, safety, tolerability, and efficacy of a new formulation of vedolizumab produced by an improved manufacturing process. METHODS:UC patients we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21896

    authors: Parikh A,Leach T,Wyant T,Scholz C,Sankoh S,Mould DR,Ponich T,Fox I,Feagan BG

    更新日期:2012-08-01 00:00:00

  • Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.

    abstract:BACKGROUND:Osteoporosis is a well-known complication of Crohn's disease (CD). Osteoprotegerin (OPG) concentration is elevated in patients with CD compared to healthy controls. Long-term infliximab (IFX) maintenance therapy improves the patients' bone mineral density. The effect of IFX on bone metabolism has not yet bee...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.20234

    authors: Miheller P,Muzes G,Rácz K,Blázovits A,Lakatos P,Herszényi L,Tulassay Z

    更新日期:2007-11-01 00:00:00

  • G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation.

    abstract:BACKGROUND:A novel family of proton-sensing G protein-coupled receptors, including OGR1, GPR4, and TDAG8, was identified to be important for physiological pH homeostasis and inflammation. Thus, we determined the function of proton-sensing OGR1 in the intestinal mucosa. MTEHODS:OGR1 expression in colonic tissues was in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000375

    authors: de Vallière C,Wang Y,Eloranta JJ,Vidal S,Clay I,Spalinger MR,Tcymbarevich I,Terhalle A,Ludwig MG,Suply T,Fried M,Kullak-Ublick GA,Frey-Wagner I,Scharl M,Seuwen K,Wagner CA,Rogler G

    更新日期:2015-06-01 00:00:00

  • Enterotoxigenic bacteroides fragilis: a potential instigator of colitis.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is proposed to result from a dysregulated mucosal immune response to the colonic flora in genetically susceptible individuals. Enterotoxigenic Bacteroides fragilis (ETBF), a molecular subclass of the common human commensal, B. fragilis, has been associated with IBD. This stud...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20265

    authors: Rabizadeh S,Rhee KJ,Wu S,Huso D,Gan CM,Golub JE,Wu X,Zhang M,Sears CL

    更新日期:2007-12-01 00:00:00

  • Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis.

    abstract:BACKGROUND:The clinical course of ulcerative colitis (UC) is unpredictable. During recent years, the ability of fecal biomarkers to predict relapse in inflammatory bowel disease has been evaluated. The objective of this study was to assess fecal calprotectin (FC) as a predictor of disease recurrence in patients with ne...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/MIB.0b013e31827e78be

    authors: Lasson A,Simrén M,Stotzer PO,Isaksson S,Ohman L,Strid H

    更新日期:2013-03-01 00:00:00

  • Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge.

    abstract:BACKGROUND:Current therapy for inflammatory bowel disease (IBD) patients often involves agents that suppress the immune system, placing patients at an increased risk for developing infections, of which several are potentially vaccine preventable. Many IBD patients are not being vaccinated appropriately. The aims of thi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21667

    authors: Wasan SK,Coukos JA,Farraye FA

    更新日期:2011-12-01 00:00:00

  • Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

    abstract::Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000444

    authors: Viennois E,Zhao Y,Merlin D

    更新日期:2015-10-01 00:00:00

  • Tissue-based Gene Expression as Potential Biomarkers for IBD Course.

    abstract::Inflammatory bowel diseases (IBDs) are highly heterogeneous in disease phenotype, behavior, and response to therapy. Diagnostic and therapeutic decisions in IBD are based primarily on clinical and endoscopic severity and histopathologic analysis of intestinal biopsies. With this approach, however, only a minority of p...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa217

    authors: Haberman Y

    更新日期:2020-09-18 00:00:00

  • Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

    abstract:BACKGROUND:Noninvasive, sensitive, and specific tools for early identification of chronic inflammatory bowel disease (IBD) are needed for clinical practice. The aim was to identify new noninvasive test combinations for characterization of IBD in children and adolescents by comparing serological responses to microbial a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20535

    authors: Ashorn S,Honkanen T,Kolho KL,Ashorn M,Välineva T,Wei B,Braun J,Rantala I,Luukkaala T,Iltanen S

    更新日期:2009-02-01 00:00:00

  • Profiling adipocytokine secretion from creeping fat in Crohn's disease.

    abstract:BACKGROUND:Adipose tissue is recognized as a compartment secreting highly active molecules. Creeping fat represents a characteristic feature of Crohn's disease (CD). Proinflammatory or anti-inflammatory adipose-derived secretory products, now generally called adipocytokines, may play a role in the pathogenesis of CD. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200606000-00005

    authors: Paul G,Schäffler A,Neumeier M,Fürst A,Bataillle F,Buechler C,Müller-Ladner U,Schölmerich J,Rogler G,Herfarth H

    更新日期:2006-06-01 00:00:00

  • CARD3 deficiency protects against colitis through reduced epithelial cell apoptosis.

    abstract:BACKGROUND:Caspase activation and recruitment domain 3 (CARD3) is a 61-kDa protein kinase. Recent evidence shows the importance of CARD3 in the immune response and inflammatory diseases. To elucidate its impact on inflammatory bowel disease, we studied the effects of the loss of CARD3 in the acute dextran sodium sulfat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000322

    authors: Yu SJ,Liu Y,Deng Y,Zhu XY,Zhan N,Dong WG

    更新日期:2015-04-01 00:00:00

  • Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

    abstract:BACKGROUND:PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS:Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izz008

    authors: Loftus EV,Reinisch W,Panaccione R,Berg S,Alperovich G,Bereswill M,Kalabic J,Petersson J,Thakkar R,Robinson AM,D'Haens G

    更新日期:2019-08-20 00:00:00

  • Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis.

    abstract:BACKGROUND:Oral ferrous iron therapy may reinforce intestinal inflammation. One possible mechanism is by catalyzing the production of reactive oxygen species. We studied the effects of low-dose oral ferrous fumarate on intestinal inflammation and plasma redox status in dextran sulfate sodium (DSS)-induced colitis in ra...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000174374.83601.86

    authors: Erichsen K,Milde AM,Arslan G,Helgeland L,Gudbrandsen OA,Ulvik RJ,Berge RK,Hausken T,Berstad A

    更新日期:2005-08-01 00:00:00

  • Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.

    abstract:BACKGROUND AND AIMS:Ulcerative colitis (UC) is a form of inflammatory bowel disease, and antibodies against tumor necrosis factor (anti-TNF) are used for treatment. Many patients are refractory or lose response to anti-TNF, and predicting response would be an extremely valuable clinical tool. Unlike most biomarkers, cy...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy358

    authors: Obraztsov IV,Shirokikh KE,Obraztsova OI,Shapina MV,Wang MH,Khalif IL

    更新日期:2019-02-21 00:00:00

  • Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know.

    abstract::The peak incidence of the inflammatory bowel diseases (IBDs) is between the second and fourth decades of life, which coincides with prime reproductive years. Unplanned or mistimed pregnancies may account for nearly half of all pregnancies and are associated with adverse consequences such as a higher risk of delayed pr...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz025

    authors: Limdi JK,Farraye J,Cannon R,Woodhams E,Farraye FA

    更新日期:2019-09-18 00:00:00

  • Skin side effects of inflammatory bowel disease therapy.

    abstract::Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clini...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0b013e3182802c07

    authors: Torres J,Buche S,Delaporte E,Colombel JF

    更新日期:2013-04-01 00:00:00

  • Point Prevalence of Pediatric Inflammatory Bowel Disease in New Zealand in 2015: Initial Results from the PINZ Study.

    abstract:BACKGROUND:The incidence of pediatric inflammatory bowel disease (IBD) around the world is increasing. However, there is a scarcity of data on the epidemiology of pediatric IBD in the Southern Hemisphere. This study aimed to document the point prevalence of pediatric IBD in New Zealand on June 30, 2015. METHODS:All pa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001138

    authors: Lopez RN,Evans HM,Appleton L,Bishop J,Chin S,Mouat S,Gearry RB,Day AS

    更新日期:2017-08-01 00:00:00

  • Outcomes of Perianal Fistulising Crohn's Disease Following Anti-TNFα Treatment Discontinuation.

    abstract:Background:Discontinuation of antitumour necrosis factor (TNF)α therapy with perianal fistulising Crohn's disease remains controversial due to the risk of severe relapse without any clear evidence. Aim:The aim of this study was to assess the rate and type of perianal and luminal relapses following anti-TNFα discontinu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy008

    authors: Legué C,Brochard C,Bessi G,Wallenhorst T,Dewitte M,Siproudhis L,Bouguen G

    更新日期:2018-05-18 00:00:00